ABBV-383 is a unique bispecific antibody engineered to target both myeloma and T cells within the immune system. It is also unique as it is given intravenously (via IV) instead of subcutaneously (via injection). It's referred to as a BCMA x CD3 bispecific antibody. BCMA is the target that ABBV-383 uses to recognize multiple myeloma cells, and CD3 is used to recognize T-cells.  

ABBV-383 Clinical Trials (July 2024)

NCT05259839: Dose Escalation and Expansion of ABBV-383 Study in Combination with Typical Myeloma Treatments

• This Phase I (1) study is for relapsed/refractory multiple myeloma patients who must never have received a prior BCMA-targeting treatment (BCMA-naive). 
• The purpose of this study is to assess the safety and toxicity of ABBV-383 when combined with pomalidomide-dexamethasone, lenalidomide-dexamethasone, daratumumab-dexamethasone, or nirogacestat (Niro) in adult participants with relapsed/refractory multiple myeloma. 
• The dose of ABBV-383 in combination with the treatments above will be tested throughout the trial. 
• Status: Actively Recruiting (as of July 2024)

NCT05650632: Studying Adverse Events (like CRS) of Intravenously (IV) Infused ABBV-383

• This Phase 1b study is for relapsed/refractory multiple myeloma patients. There are two arms to this trial. The first arm will enroll BCMA-naive patients, while the other arm allows patients who have received prior BCMA-targeting therapy, such as CAR T-cell therapy or anti-drug conjugate therapy. 
• The purpose of this study is to determine adverse events, such as cytokine release syndrome (CRS), and changes in disease symptoms of ABBV-383 in relapsed/refractory multiple myeloma patients.
• Status: Actively Recruiting (as of July 2024)

For more or updated information on these clinical trials, check out our HealthTree Myeloma Clinical Trial Finder. 

Learn more about ABBV-383

Interview filmed at ASH in December 2023.